Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis

To investigate the frequency and clinical characteristics of autoantibody formation and development of autoimmune thyroid disease after interferon therapy, we measured the autoantibodies to thyrotropin receptor (TBII), thyroglobulin (ATA), and microsomal antigen (AMA) in 28 patients with histologica...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of gastroenterology Vol. 88; no. 2; p. 244
Main Authors Chung, Y H, Shong, Y K
Format Journal Article
LanguageEnglish
Published United States 01.02.1993
Subjects
Adult
Autoantibodies - immunology
Autoantigens - immunology
Autoimmune Diseases - immunology
Autoimmunity
Chronic Disease
Female
Graves Disease - etiology
Graves Disease - immunology
Hepatitis B - therapy
Hepatitis C - therapy
Hepatitis, Viral, Human - therapy
Humans
Interferon-alpha - adverse effects
Interferon-alpha - therapeutic use
Male
Middle Aged
Recombinant Proteins
Thyroid Gland - immunology
Online AccessGet more information

Cover

More Information
Summary:To investigate the frequency and clinical characteristics of autoantibody formation and development of autoimmune thyroid disease after interferon therapy, we measured the autoantibodies to thyrotropin receptor (TBII), thyroglobulin (ATA), and microsomal antigen (AMA) in 28 patients with histologically proven chronic viral hepatitis [25 males, three females; mean age 38.7 +/- 8.7 (SD) yr] receiving recombinant interferon-alpha 2b (IFN-alpha) treatment. Twenty patients with chronic hepatitis B (positive for HBsAg, HBeAg, and HBV DNA) and eight patients with chronic hepatitis C (positive for anti-HCV and HCV RNA) received IFN-alpha, 3 million units subcutaneously, three times a week for 6 months. Before, during, and up to 6 months after IFN-alpha therapy, thyroid hormone levels and titers of AMA, ATA, and TBII were measured every 2 months. None of them had thyroid dysfunction or antithyroid autoantibodies before IFN-alpha treatment. A 34-yr-old male patient developed Graves' disease during the last month of therapy. He required long-term antithyroid medications, even after discontinuation of IFN-alpha. Another 44-yr-old female patient developed AMA during IFN-alpha treatment; however, thyroid function remained normal and goiter did not develop in this patient. No other patient developed thyroid autoantibodies and thyroid dysfunction. In summary, only a small minority of patients will develop thyroid autoimmunity during IFN-alpha therapy, and much less often with this low dose of IFN-alpha.
ISSN:0002-9270